[go: up one dir, main page]

MX2024010674A - Compuestos de quinolina antagonistas de cgas. - Google Patents

Compuestos de quinolina antagonistas de cgas.

Info

Publication number
MX2024010674A
MX2024010674A MX2024010674A MX2024010674A MX2024010674A MX 2024010674 A MX2024010674 A MX 2024010674A MX 2024010674 A MX2024010674 A MX 2024010674A MX 2024010674 A MX2024010674 A MX 2024010674A MX 2024010674 A MX2024010674 A MX 2024010674A
Authority
MX
Mexico
Prior art keywords
quinoline
antagonist compounds
cgas
compounds
cgas antagonist
Prior art date
Application number
MX2024010674A
Other languages
English (en)
Inventor
Qi Wei
Heping Shi
Matt Tschantz
Jian Qiu
youtong Wu
Huiling Tan
Lijun Sun
Chuo Chen
Zhijian Chen
Original Assignee
Immunesensor Therapeutics Inc
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunesensor Therapeutics Inc, Univ Texas filed Critical Immunesensor Therapeutics Inc
Publication of MX2024010674A publication Critical patent/MX2024010674A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación proporciona compuestos que son antagonistas de cGAS, métodos de preparación de los compuestos, composiciones farmacéuticas que comprenden los compuestos y su uso en terapia médica.
MX2024010674A 2022-03-02 2024-08-30 Compuestos de quinolina antagonistas de cgas. MX2024010674A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263315968P 2022-03-02 2022-03-02
US202363478467P 2023-01-04 2023-01-04
PCT/US2023/063623 WO2023168367A1 (en) 2022-03-02 2023-03-02 QUINOLINE cGAS ANTAGONIST COMPOUNDS

Publications (1)

Publication Number Publication Date
MX2024010674A true MX2024010674A (es) 2024-11-08

Family

ID=85781707

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010674A MX2024010674A (es) 2022-03-02 2024-08-30 Compuestos de quinolina antagonistas de cgas.

Country Status (11)

Country Link
US (2) US12281078B2 (es)
EP (1) EP4486734A1 (es)
JP (1) JP2025507820A (es)
KR (1) KR20250004639A (es)
CN (1) CN119137112A (es)
AU (1) AU2023228915A1 (es)
CA (1) CA3253386A1 (es)
IL (1) IL315346A (es)
MX (1) MX2024010674A (es)
TW (1) TW202342021A (es)
WO (1) WO2023168367A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022051634A1 (en) 2020-09-03 2022-03-10 Immunesensor Therapeutics, Inc. Quinoline cgas antagonist compounds
IL315346A (en) 2022-03-02 2024-11-01 Immunesensor Therapeutics Inc CGAS agonistic quinoline compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3542785A (en) 1967-05-15 1970-11-24 Ciba Geigy Corp 2-hydroxy-4-aryl-quinolines
US3668207A (en) 1970-01-22 1972-06-06 Ciba Geigy Corp 2-amino-4-aryl-quinolines
MXPA05000081A (es) * 2002-06-27 2005-04-11 Schering Ag Quinolinas sustituidas antagonistas del receptor ccr5.
MX2010003001A (es) 2007-09-27 2010-04-01 Hoffmann La Roche Derivados de quinolina como antagonistas del receptor de la 5-hidroxitriptamina 5a.
CN108602798A (zh) * 2015-12-14 2018-09-28 基础应用医学研究基金会 作为dna甲基转移酶抑制剂的2,4,6,7-四元取代的喹啉化合物
CN109111426B (zh) 2017-06-23 2021-12-14 中国科学院上海药物研究所 一类稠合双环杂芳基或芳基化合物，及其用途
PL3678668T3 (pl) 2017-09-08 2024-06-03 The Board Of Trustees Of The Leland Stanford Junior University Inhibitory enpp1 i ich zastosowanie w leczeniu nowotworu
WO2019241787A1 (en) 2018-06-15 2019-12-19 The Regents Of The University Of Colorado A Body Corporate Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use
EP3829581B1 (en) 2018-07-27 2024-04-03 Arcus Biosciences, Inc. Pyridone a2r antagonists
EP3620164A1 (en) * 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
KR20210112317A (ko) 2019-01-04 2021-09-14 벨부르크 랩스, 엘엘씨 치료제로서의 cgas 활성 억제제
EP4076667A1 (en) 2019-12-20 2022-10-26 Erasca, Inc. Tricyclic pyridones and pyrimidones
JP2023518648A (ja) 2020-01-20 2023-05-08 クレセンタ バイオサイエンシズ 細胞代謝を調節する新規化合物およびその使用
CN116615189A (zh) * 2020-07-06 2023-08-18 新月生物科学 新型细胞代谢调节化合物及其用于治疗病毒疾病的用途
WO2022051634A1 (en) * 2020-09-03 2022-03-10 Immunesensor Therapeutics, Inc. Quinoline cgas antagonist compounds
IL315346A (en) 2022-03-02 2024-11-01 Immunesensor Therapeutics Inc CGAS agonistic quinoline compounds

Also Published As

Publication number Publication date
US12091387B2 (en) 2024-09-17
CA3253386A1 (en) 2023-09-07
EP4486734A1 (en) 2025-01-08
KR20250004639A (ko) 2025-01-08
US20240002346A1 (en) 2024-01-04
WO2023168367A1 (en) 2023-09-07
AU2023228915A1 (en) 2024-09-19
TW202342021A (zh) 2023-11-01
JP2025507820A (ja) 2025-03-21
US20230357158A1 (en) 2023-11-09
IL315346A (en) 2024-11-01
US12281078B2 (en) 2025-04-22
CN119137112A (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
ZA202304064B (en) Quinoline cgas antagonist compounds
MX2024010674A (es) Compuestos de quinolina antagonistas de cgas.
ZA202103587B (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
MX2022012178A (es) Compuestos, composiciones farmaceuticas y metodos para la preparacion de compuestos y para su uso.
PH12022550098A1 (en) Parp1 inhibitors
EP4523755A3 (en) Quinazoline derivatives as antitumor agents
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
IL314347A (en) Combined treatment of lasmiditan and a CGRP antagonist for use in the treatment of migraine
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
PH12022551359A1 (en) Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2020010568A (es) Derivados de urea ciclica fusionada como antagonista de crhr2.
PH12022551468A1 (en) Compounds active towards nuclear receptors
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
PH12019502086A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
JOP20220107A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
JOP20200014A1 (ar) توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf
MX2024013184A (es) Metodos y composiciones para tratar apnea del sue?o
PH12021553177A1 (en) Pharmaceutical composition for treating tumor
MX2020007559A (es) Formulaciones farmaceuticas.
MX2022007516A (es) Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos.
MX2024012565A (es) Composiciones farmaceuticas de mosunetuzumab y metodos de uso